Pfizer (PFE): The Bull Case Beyond the Patent Cliff

A recent analysis makes the case for Pfizer despite the looming patent cliff. CEO Albert Bourla is effectively betting his tenure on the company's pipeline and cost-cutting plan.

Pfizer faces patent expirations on several blockbusters, including the blood thinner Eliquis and the cancer drug Ibrance. Those drugs together account for a significant share of revenue. The loss of exclusivity is a known headwind.

The bull case rests on new drugs in the pipeline, including potential approvals in oncology and vaccines, and on a cost-cutting program that aims to save billions. Bourla has staked his strategy on these moves.

AlphaScala's proprietary model gives PFE a score of 49 out of 100, labeled Mixed. That reflects the balance between pipeline potential and the revenue erosion from expiring patents.